Shares of Second Sight Medical Products Inc. (NASDAQ:EYES) were down 3.3% on Wednesday . The stock traded as low as $3.55 and last traded at $3.56, with a volume of 93,318 shares trading hands. The stock had previously closed at $3.68.

A number of equities research analysts have recently issued reports on EYES shares. Zacks Investment Research raised Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Friday, June 24th. Rodman & Renshaw reaffirmed a “buy” rating and set a $16.00 target price on shares of Second Sight Medical Products in a research report on Tuesday, July 26th.

The firm’s 50-day moving average is $3.95 and its 200-day moving average is $4.39. The firm’s market cap is $140.52 million.

Second Sight Medical Products (NASDAQ:EYES) last released its quarterly earnings results on Thursday, July 28th. The medical device company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by $0.02. During the same period last year, the company earned ($0.12) earnings per share. The company earned $1.04 million during the quarter, compared to analysts’ expectations of $2.66 million. Second Sight Medical Products’s quarterly revenue was down 63.0% on a year-over-year basis. On average, equities research analysts predict that Second Sight Medical Products Inc. will post ($0.62) EPS for the current fiscal year.

In related news, Chairman Robert J. Greenberg sold 8,571 shares of the firm’s stock in a transaction on Thursday, June 2nd. The stock was sold at an average price of $4.10, for a total transaction of $35,141.10. Following the completion of the sale, the chairman now directly owns 172,911 shares of the company’s stock, valued at approximately $708,935.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.